Clinical Trial to to Compare of the Efficacy and Safety of Lipilou® 20 mg and Lipilou® 10 mg
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: Lipilou®(generic atorvastatin drug) 20 mgDrug: Lipilou®(generic atorvastatin drug) 10 mg
- Registration Number
- NCT04511000
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Brief Summary
This study was designed to compare the mean percent change of LDL-C between Lipilou® 10mg and 20mg group after 12 weeks of treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 250
- Patients who had hypercholesterolemia with high risk, according to the 2015 Korean guidelines for managing dyslipidemia.
- Patients with uncontrolled diabetes mellitus, uncontrolled hypertension, thyroid dysfunction.
- Patients who are legally unable to participate in clinical trials or who are unable to participate in clinical trials based on investigator's decision.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Experimental group Lipilou®(generic atorvastatin drug) 20 mg - Comparator group Lipilou®(generic atorvastatin drug) 10 mg -
- Primary Outcome Measures
Name Time Method Change rate in LDL-C 12 weeks of treatment compare experimental group with comparator group
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (10)
Korea University Ansan Hospital
🇰🇷Ansan, Korea, Republic of
Dong-A University Hospital
🇰🇷Busan, Korea, Republic of
Sejong General Hospital
🇰🇷Bucheon, Korea, Republic of
Myongji Hospital
🇰🇷Goyang, Korea, Republic of
Korea University Guro Hospital
🇰🇷Seoul, Korea, Republic of
Seoul National University Bundang Hospital
🇰🇷Seongnam, Korea, Republic of
Inje University Ilsan Paik Hospital
🇰🇷Goyang, Korea, Republic of
Ulsan University Hospital
🇰🇷Ulsan, Korea, Republic of
Wonju Severance Christian Hospital
🇰🇷Wŏnju, Korea, Republic of
Pusan National University Yangsan Hospital
🇰🇷Yangsan, Korea, Republic of